Pernix Therapeutics Holdings Inc  

(Public, NASDAQ:PTX)   Watch this stock  
Find more results for NYSEAMEX:PTX
7.47
-0.10 (-1.32%)
Sep 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.25 - 7.88
52 week 1.68 - 9.56
Open 7.62
Vol / Avg. 705,167.00/446,559.00
Mkt cap 287.99M
P/E     -
Div/yield     -
EPS -0.73
Shares 38.04M
Beta 1.64
Inst. own 62%
Aug 20, 2014
Pernix Therapeutics Holdings Inc Closes Acquisition of Treximet Conference Call - Webcast
Aug 11, 2014
Q2 2014 Pernix Therapeutics Holdings Inc Earnings Call
Aug 11, 2014
Q2 2014 Pernix Therapeutics Holdings Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -35.86% -30.20%
Operating margin -44.58% -64.40%
EBITD margin - -31.04%
Return on average assets -9.80% -11.08%
Return on average equity -25.01% -27.09%
Employees 191 -
CDP Score - -

Address

SUITE 201, 884 JOHNNIE DODDS BLVD
MOUNT PLEASANT, SC 29464
United States - Map
+1-832-9341825 (Phone)
+1-800-7932145 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Pernix Therapeutics Holdings, Inc. (Pernix) is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products for pediatric and adult indications in a range of therapeutic areas. It manages a portfolio of branded and generic products and theobromine, a non-codeine, cough suppressant product candidate in development. The Company�s branded products for the pediatrics market include CEDAX, an antibiotic for middle ear infections, NATROBA, a topical treatment for head lice marketed under an exclusive co-promotion agreement with ParaPRO, LLC and a family of prescription treatments for cough and cold (BROVEX, ALDEX and PEDIATEX). In August 2014, the Company acquired Treximet(reg) (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults.

Officers and directors

Douglas Drysdale Chairman of the Board, President, Chief Executive Officer
Age: 44
Bio & Compensation  - Reuters
Sanjay Patel Chief Financial Officer
Bio & Compensation  - Reuters
Terence S. Novak Chief Operating Officer
Age: 57
Bio & Compensation  - Reuters
Rick Shalaby Senior Vice President - Sales and Marketing
Age: 46
Bio & Compensation  - Reuters
Brian T. Dorsey Senior Vice President - Research & Development
Age: 45
Bio & Compensation  - Reuters
Tracy Simmons Clifford Chief Accounting Officer
Age: 45
Bio & Compensation  - Reuters
Steven A. Elms Independent Director
Age: 50
Bio & Compensation  - Reuters
Tasos G. Konidaris Non-Executive Independent Director
Age: 47
Bio & Compensation  - Reuters
John A. Sedor Non-Executive Independent Director
Age: 69
Bio & Compensation  - Reuters